Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
← catalyst calendarNCT06531109 · readout in 605 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
450estimated
Sites
81
Countries
China, France, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-07 | actual | When the study began enrolling |
| Primary completion | 2028-04-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Intervention
- Drug: Ritlecitinib
Primary outcome
what the primary-completion date above is the date OFPercentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24
measured 24 weeks from initiation of the treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed